ApoB/A1 and LDL-C/HDL-C and the prediction of cardiovascular risk in statin-treated patients

References

• Lamarche B, Moorjani S, Lupien PJ, et al. Apoprotein A-1 and B levels and the risk of ischemic heart disease during a 5-year follow-up of men in the Quebec Cardiovascular Study. Circulation 1996;94:273–8
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001;358:2026–33
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). Lancet 2004;364: 937–52
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Furberg CD, Keech A, et al. Apoproteins versus lipids as indices of coronary risk and as targets for statin therapy: analysis of the evidence. Lancet 2003;36:777–80
   Google Scholar
• Roeters van Lennep JE, Westerveld HT, Roeters van Lennep HW, et al. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 2000;20:2408–13
   PubMed Web of Science ®Google Scholar
• Gotto AM, Whitney E, Stein EA, et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Airforce/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 2000;101:477–84
   PubMed Web of Science ®Google Scholar
• Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in the ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002;105:1162–9
   Google Scholar
• Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med 2004;255:188–205
   PubMed Web of Science ®Google Scholar
• Srivastava RAK, Srivastava N. High density lipoprotein, apolipoprotein A-I, and coronary artery disease. Mol Cell Biochem 2000; 209:131–44
   PubMed Web of Science ®Google Scholar
• Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry 1988;27:25–9
   PubMed Web of Science ®Google Scholar
• Lee JY, Parks JS. ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 2005;16: 19–25
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39
   PubMed Web of Science ®Google Scholar
• Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. Secondary prevention with folic acid: results of the Goes extension study. Heart 2005;91:1213–14
   PubMed Web of Science ®Google Scholar
• Ad Hoc Committee on Cerebrovascular Disease./person-group>. A classification and outline of cerebrovascular diseases II. Stroke 1975;6: 564–616
   PubMedGoogle Scholar
• Moise A, Clement B, Ducimetière P, Bourassa MG. Comparison of receiver operating curves derived from the same population: a bootstrapping approach. Comput Biomed Res 1985;18: 125–31
   Google Scholar
• Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York: Chapman & Hall/CRC Press, 1993
   Google Scholar
• Stein EA, Sniderman A, Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 2005;96:36–43
   Google Scholar
• Barter PJ, Ballantyne CM, Carmena R, et al. Report of the thirty person/ten country panel. ApoB versus cholesterol to estimate cardiovascular risk and to guide therapy. J Intern Med 2006;259:247–58
   Google Scholar
• Sniderman AD, St-Pierre A, Cantin B, et al. Concordance/ discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003;91:1173–7
   PubMed Web of Science ®Google Scholar
• Sniderman AD. How, when and why to use apolipoprotein B in clinical practice. Am J Cardiol 2002;90(Suppl):48–54i
   Google Scholar
• Van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007;146:640–8
   PubMed Web of Science ®Google Scholar
• Ingelsson E, Schaefer EJ, Contois JH, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007;298:776–85
   PubMed Web of Science ®Google Scholar
• Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332;1115–24
   Google Scholar
• Cook NR./person-group>. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007;115:928–35
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy – a review of the evidence. J Intern Med 2006;259:493–519
   PubMed Web of Science ®Google Scholar